The British Biotech- Ixico established in 2004 focuses on clinical data management and analysis for neurodegenerative diseases such as Huntington’s, multiple sclerosis and Alzheimer’s, as well as the diagnosis and management of dementia in clinical practice as an offspring, the company also has commercial relationships with nine of the top 15 pharma companies.
This successful biotech has been providing end-to-end imaging services to the biopharma industry, academia and medical charities since 2004 and in 2013, through a reverse takeover of Phytopharm, Ixico embarked on London Stock Exchange’s AIM for smaller growing companies.
This neuroscience-focused digital technology company has now announced that it has signed a contract with Spanish biotech Araclon for imaging clinical trial services.
Araclon’s Alzheimer’s vaccine candidate dubbed ABvac40, is now in Phase II of trials and it targets the amyloid-beta 40 protein using the C-terminal part of the amyloid-beta peptide as vaccine antigen instead of the N-terminal fragment, which most other therapies under development are aiming at.
Here, Ixico will be using its imaging data management platform TrialTracker to collate results from positron emission tomography (PET) and MRI scans, and its patent-protected image analysis technology to evaluate patient eligibility, assess target engagement and quantify drug effects in
patients.The current phase II intends to determine the dosage and the drug’s safety and tolerability observed in phase I. Additionally, Araclon also has an immunotherapy against the amyloid-beta-42 protein later in its pipeline.
